Alnylam Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.

CEO

Yvonne L. Greenstreet

CEOYvonne L. Greenstreet

Employees

2,500

Employees2,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2002

Founded2002

Employees

2,500

Employees2,500

ALNY Key Statistics

Market cap

21.14B

Market cap21.14B

Price-Earnings ratio

7.91

Price-Earnings ratio7.91

Dividend yield

—

Dividend yield—

Average volume

4.04M

Average volume4.04M

High today

$159.45

High today$159.45

Low today

$154.30

Low today$154.30

Open price

$155.21

Open price$155.21

Volume

386.78K

Volume386.78K

52 Week high

$479.79

52 Week high$479.79

52 Week low

$154.30

52 Week low$154.30

Stock Snapshot

As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $157.84. The company's market cap stands at 21.14B, with a P/E ratio of 7.91.

As of 2026-11-06, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $154.30 and $159.45. The current price stands at $157.84, placing the stock +2.3% above today's low and -1.0% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 386.78K, compared to an average daily volume of 4.04M.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $479.79 and a 52-week low of $154.30.

ALNY News

Simply Wall St 4h

Why Alnylam Pharmaceuticals Bears Were Right Before A 65% Drop - Simply Wall St

...

Benzinga 1d

Top 3 Health Care Stocks You'll Regret Missing In Q4

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

Simply Wall St 2d

Should Five Year AMVUTTRA Data Require Action From Alnylam Stock Investors?

Alnylam Pharmaceuticals reported Q3 2026 revenue of US$1,458.09m and net income of US$2,167.34m, while highlighting upcoming presentations of extensive long ter...

Analyst ratings

67%

of 33 ratings

Buy

66.7%

Hold

33.3%

Sell

More ALNY News

Simply Wall St 3d

Can Alnylam Pharmaceuticals Justify Its Price After A 62% Fall?

has seen its share price fall sharply over the past year, even as fresh clinical data and earnings headlines keep arriving. This puts the focus squarely on whet...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.